Can MCAS Cause Chronic Congestion and Post-Nasal Drainage?

Dr. Franklyn R. Gergits, MBA, DO, FAOCO · Board-Certified Otolaryngologist · Fellowship-Trained Otolaryngic Allergist · 30+ Years of Experience · Clinical Focus in Rhinology and Airway Disorders

Short answer: Yes — it can. Mast cell activation can absolutely contribute to nasal congestion and post-nasal drainage. I see it clinically. But congestion alone doesn’t get you to MCAS. Not even close. When I evaluate this in Scottsdale or Phoenix, I’m looking for a broader pattern — multiple systems involved, not just the nose acting up.

I’ve been doing this for over 30 years now — Pennsylvania first, now North Scottsdale — and MCAS is one of those diagnoses that has become far more common in conversation than in confirmed clinical reality.

Patients come in with a very familiar story.

Chronic congestion. Post-nasal drip. Normal CT. Negative allergy testing. And they’ve usually already been through several treatment cycles.

At some point, MCAS shows up in their research.

And honestly — I understand why.

But that doesn’t mean it’s the answer.

I don’t start with MCAS. I rarely do.

I start with anatomy, inflammation patterns, reflux contribution, nerve-driven nasal dysfunction — the usual ENT landscape.

MCAS only enters the conversation when things don’t behave like a single-system problem.

And I mean that literally.

If it’s just the nose — I’m not thinking mast cells first.

If it’s nose + skin flushing, or nose + GI symptoms, or nose + tachycardia episodes — now we’re talking about something systemic.

That’s the shift.

Not the congestion itself.

This is where people get tripped up.

Congestion and drainage are extremely non-specific symptoms.

I can see them in:

• non-allergic rhinitis

• reflux-related inflammation

• structural obstruction

• posterior nasal nerve overactivity

• chronic inflammatory sinus disease

• and yes — mast cell activation

So I don’t anchor on the nose.

I look for pattern spread.

If mast cells are involved, you usually don’t get a single-organ story. You get episodes that “spill over” into other systems.

Skin. GI tract. Cardiovascular symptoms. Sometimes neurologic sensations that patients struggle to describe.

That clustering matters more than any single nasal complaint.

Mechanistically, it’s not complicated.

Mast cells sit in the nasal mucosa. When they activate, they release histamine and a cascade of inflammatory mediators.

Histamine is the big one clinically — vascular dilation, swelling, congestion.

But it’s not acting alone. Leukotrienes, prostaglandins — they all contribute to that “blocked and runny at the same time” feeling patients describe.

And the turbinates respond fast.

They’re vascular tissue. They swell. They narrow the airway. Sometimes dramatically.

So yes — the physiology absolutely supports nasal symptoms in MCAS.

The question is whether that’s the driver or just part of a larger systemic event.

This is where my thinking has evolved.

I’ve been working with what I call Posterior Sinonasal Syndrome — a model where posterior nasal inflammation may be driven by upstream factors like refluxate exposure, including pepsin.

Now, could MCAS overlap with that?

Possibly.

But I don’t treat them as competing diagnoses.

I treat them as different layers of inflammation.

One is systemic mediator-driven.
The other may be local mucosal injury with secondary inflammatory amplification.

And clinically — patients can look similar.

That’s the problem.

This is where expectations and reality diverge.

MCAS is not a symptom-based diagnosis.

It requires:

• recurrent episodes

• involving more than one organ system

• objective mediator elevation during an event

• and clinical response to mediator-targeted therapy

The hardest part is the timing.

You need labs during the episode. Not after. Not days later.

During.

And that’s just not how real life works for most patients.

So we end up relying on patterns, history, and selective testing — which is why this diagnosis is often debated.

Not because it doesn’t exist.

Because it’s hard to capture cleanly.

If I suspect MCAS, I don’t jump straight to labeling.

I try to document:

• what systems are involved

• whether episodes are reproducible

• whether there’s a trigger pattern

• and whether symptoms cluster in time

Then I may use:

• acute and baseline tryptase (when possible)

• selected mediator testing

• and a structured therapeutic trial of H1/H2 blockade or mast-cell stabilizing therapy

But I’m careful here.

Response to antihistamines is not diagnostic.

It just tells me histamine is part of the symptom pathway — which is true in a lot of conditions.

Can MCAS cause congestion if allergy testing is negative?
Yes. MCAS is not an IgE-mediated allergy process. So testing can be completely negative and still not rule it out. But negative allergy testing alone doesn’t point toward MCAS either — it just removes one category.

Does a normal tryptase rule it out?
No. Timing is everything. You need comparison between baseline and event levels. A single normal value is not enough.

Why do ENT symptoms overlap so much between conditions?
Because the nasal mucosa is reactive tissue. It responds to neural, inflammatory, allergic, and systemic signals. That’s why diagnosis requires pattern recognition, not symptom lists.

If antihistamines help, does that confirm MCAS?
No. It only tells you histamine is involved somewhere in the pathway. That’s not specific to MCAS.

→ Is Mast Cell Activation Syndrome the Reason Your Sinuses Never Fully Clear?

→ Is It Allergies or MCAS? How an ENT Tells the Difference

→ Why Do Allergy Symptoms Keep Changing — and Nothing Works?

→ Will Balloon Sinuplasty Correct My Post-Nasal Drainage?

→ What Is NEUROMARK, and Could It Stop Your Chronic Drainage?

Dr. Franklyn R. Gergits, MBA, DO, FAOCO is a Board-Certified Otolaryngologist and Fellowship-Trained Otolaryngic Allergist with over 30 years of clinical experience. He is the founder of the Sinus & Allergy Wellness Center of North Scottsdale, where he performs in-office balloon sinuplasty, turbinate reduction, NEUROMARK® posterior nasal nerve ablation, and Eustachian tube dilation under local anesthesia. He performed the first balloon sinuplasty in Pennsylvania and holds dual Entellus Centers of Excellence certifications. His current clinical research focuses on posterior nasal inflammatory disease and the role of pepsin-mediated injury in chronic rhinosinusitis (Posterior Sinonasal Syndrome hypothesis). ORCID: 0009-0000-4893-6332.

SinusAndAllergyWellnessCenter.com · 480-525-8999

This content is for educational purposes only and does not constitute medical advice. MCAS is a complex systemic condition requiring individualized evaluation and appropriate laboratory correlation.